GCIA
JNCE

Gabelli & Co Investment Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-425,100
Closed -$786K – 313
2023
Q1 		$786K Buy
+425,100
New +$527K 0.15% 86

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Gabelli & Co Investment Advisers's JNCE Position: Q2 2023 in Review

Gabelli & Co Investment Advisers sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 425,100 shares — an estimated $786K sold.

Gabelli & Co Investment Advisers first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $786K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Gabelli & Co Investment Advisers reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 425,100 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $786K.
  • Gabelli & Co Investment Advisers first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Jounce Therapeutics, Inc. Common Stock position peaked at $786K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.